Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL552474 | 0.91 | ALDH1A1 (0.53) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL10443684 | 0.91 | CA12 (0.57) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL17400409 | 0.89 | HSD17B1 (0.56) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL30583381 | 0.88 | BRD4 (0.55) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL31337617 | 0.88 | BRD4 (0.55) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL2653935 | 0.86 | ALDH1A1 (0.54) | SRD5A1ALDH1A1MAPK1ESR1MAPT | |
| SCHEMBL38659727 | 0.86 | ALDH1A1 (0.54) | SRD5A1ALDH1A1MAPK1ESR1MAPT | |
| SCHEMBL13798314 | 0.84 | CA12 (0.50) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 | |
| SCHEMBL4916631 | 0.83 | MAPT (0.58) | ALDH1A1MAPK1CA12CA1CA2 | |
| SCHEMBL1918550 | 0.83 | MAPT (0.58) | SRD5A1SRD5A2ALDH1A1MAPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013808-B1 | ISOTHIAZOLINE COMPOUNDS SUBSTITUTED WITH A CARBOBICYCLIC GROUP | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-04-15 | — | — | EP | disclosed |
| US-9387203-B2 | Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-3013808-A1 | ISOTHIAZOLINE COMPOUNDS SUBSTITUTED WITH A CARBOBICYCLIC GROUP | Merial, Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | US | disclosed |
| WO-2014206908-A1 | ISOTHIAZOLINE COMPOUNDS SUBSTITUTED WITH A CARBOBICYCLIC GROUP | BASF SE (DE) | 2014-12-31 | — | — | WO | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| EP-1802577-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006062580-A1 | INDANE AMIDES WITH ANTIPROLIFERATIVE ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174113-A1 | SUBSTITUTED AMINOINDANE- AND AMINOTETRALINECARBOXYLIC ACIDS AND THE USE THEREOF | AADAT, DDC, AASDHPPT | SRD5A1 1444/4885SRD5A2 1760/4885ALDH1A1 1430/4885 |
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | SRD5A1 1120/4885SRD5A2 809/4885ALDH1A1 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.